

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-51. (Canceled)

52. (Currently amended) A method for controlling entry of a flavivirus into a cell, the flavivirus exhibiting a flavivirus envelope protein, the flavivirus envelope protein comprising a domain III of the flavivirus envelope protein, the method comprising administering to the cell an agent that functionally interferes with binding of the domain III of the flavivirus envelope protein to a flavivirus receptor protein, wherein the agent comprises a polypeptide having an amino acid sequence that exhibits at least 80% sequence ~~similarity-identity~~ to amino acids 350 to 390 of a flavivirus envelope sequence as set forth in SEQ ID NO: 21, and wherein the flavivirus receptor protein is one of an integrin and a neurotensin receptor.

53. (Previously presented) The method of claim 52, wherein the domain III comprises a sequence that is substantially homologous to SEQ ID NO: 21.

54. (Canceled)

55-70. (Canceled)

71. (Previously presented) The method of claim 52, wherein the flavivirus is selected from the group consisting of Japanese Encephalitis Virus, West Nile Virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, Dengue virus and Kunjin virus.

72. (Previously presented) The method of claim 52, wherein the flavivirus receptor protein is an integrin.

73. (Previously presented) The method of claim 72, wherein in the integrin comprises at least one subunit selected from the group consisting of integrin subunit αV , integrin subunit $\beta 3$ and integrin subunit $\beta 5$.

74. (Previously presented) The method of claim 52, wherein the flavivirus receptor protein is a neurotensin receptor.

75. (Previously presented) The method of claim 52, wherein the agent is a ligand of the flavivirus receptor protein.

76. (Previously presented) The method of claim 75, wherein the ligand competes with the flavivirus envelope protein domain III for the binding of the domain III of the flavivirus envelope protein to the flavivirus receptor protein

77. (Currently amended) The method of claim 52, wherein the agent comprises a polypeptide having an amino acid sequence that exhibits at least 85% sequence ~~similarity-identity~~ to amino acids 350 to 390 of a flavivirus envelope sequence as set forth in SEQ ID NO: 21.

78. (Currently amended) The method of claim 52, wherein the agent comprises a polypeptide having an amino acid sequence that exhibits at least 90% sequence ~~similarity-identity~~ to amino acids 350 to 390 of a flavivirus envelope sequence as set forth in SEQ ID NO: 21.

79. (Currently amended) The method of claim 52, wherein the agent comprises a polypeptide having an amino acid sequence that exhibits at least 95% sequence

~~similarity-identity~~ to amino acids 350 to 390 of a flavivirus envelope sequence as set forth in SEQ ID NO: 21.

80. (Currently amended) The method of claim 52, wherein the agent comprises a polypeptide having an amino acid sequence that exhibits at least 98% sequence ~~similarity-identity~~ to amino acids 350 to 390 of a flavivirus envelope sequence as set forth in SEQ ID NO: 21.

81. (Previously presented) The method of claim 52, wherein the agent comprises a polypeptide having an amino acid sequence that exhibits complete identity to amino acids 350 to 390 of a flavivirus envelope sequence as set forth in SEQ ID NO: 21.